Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Testing, Pathogen Inactivation Or Both? Experts Predict Blood Safety’s Future

This article was originally published in The Gray Sheet

Executive Summary

Pathogen inactivation likely will supersede testing as the primary method of preventing the spread of pathogens through blood transfusions in the developing world, according to participants at a June 4 transfusion safety symposium at NIH

You may also be interested in...

Pathogen Reduction Will Not Replace Screening In Near Term – FDA’s Epstein

Blood pathogen reduction technology may benefit only non-immunosuppressed patients if FDA determines that the inactivation agents pose a toxicological risk

Stockwatch: The Post-Pandemic Dynamics Of Coronavirus Vaccines

Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts